Cardamonin
Based on 19 publication(s) in Google Scholar
Cardamonin can be found from cardamom, and can target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.80%
- CAS No.: 18956-16-6
- Formule: C16H14O4
- Masse moléculaire:270.28
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-90006
5-FluorouracilThymidylate Synthase Inhibitor -
HY-14590
KaempferolEstrogen Receptor α Inhibitor -
HY-N0196
BaicaleinXanthine Oxidase Inhibitor -
HY-D1056
Lipopolysaccharides, from E. coli O55:B5Endotoxin -
HY-N1378
(E)-CardamoninhTRPA1 Antagonist -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-N0523
Gallic acidBioactive Polyhydroxyphenolic Compound -
HY-N0109
SalidrosideProlyl Endopeptidase Inhibitor -
HY-117287
DeucravacitinibTYK2 Inhibitor -
HY-N0100
NaringeninFlavonoid -
HY-B0089
AcarboseAlpha-Glucosidase Inhibitor -
HY-18085
QuercetinFlavonoid Antioxidant
Publications Citing Use of MedChemExpress (MCE) Cardamonin
More- Acta Pharm Sin B. 2024 Mar;14(3):1241-1256. [Abstract]
- Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
- Pharmacol Res. 2020 May:155:104751. [Abstract]
- Phytomedicine. 2025 Dec:149:157512. [Abstract]
- Phytomedicine. 2024 Nov:134:155970. [Abstract]
- Antioxidants (Basel). 2024 Jul 19;13(7):864. [Abstract]
- Phytother Res. 2022 Apr;36(4):1736-1747. [Abstract]
- J Agric Food Chem. 2023 Sep 13;71(36):13284-13303. [Abstract]
- Food Funct. 2024 Nov 11;15(22):11083-11095. [Abstract]
- Food Funct. 2021 Nov 29;12(23):11808-11818. [Abstract]
- Nutrients. 2021 Sep 26;13(10):3382. [Abstract]
- Int J Mol Sci. 2025 Dec 25;27(1):249. [Abstract]
- ACS Omega. 2026 Apr 13;11(16):23820-23832. [Abstract]
- Sci Rep. 2025 Aug 12;15(1):29484. [Abstract]
- Pathol Res Pract. 2026 May 24:286:156558. [Abstract]
- Toxicol Appl Pharmacol. 2026 Mar:508:117731. [Abstract]
- Toxicol In Vitro. 2023 Sep:91:105625. [Abstract]
- Neurol Res. 2025 Nov 25:1-17. [Abstract]
- Biomed Pharmacother. 2020 Feb:122:109547. [Abstract]
Customer Validation & Images
-
WB
-
WB
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16-F10 | IC50 |
0.6 μM
Compound: 139
|
Antiinflammatory activity in mouse B16-F10 cells assessed as decrease in LPS-induced TNFalpha expression by Western blot analysis
Antiinflammatory activity in mouse B16-F10 cells assessed as decrease in LPS-induced TNFalpha expression by Western blot analysis
|
[PMID: 37683361] |
| CCRF-CEM | IC50 |
≤10 μM
Compound: 64
|
Cytotoxicity in human CCRF-CEM cells by resazurin reduction assay
Cytotoxicity in human CCRF-CEM cells by resazurin reduction assay
|
[PMID: 28793973] |
| DLD-1 | IC50 |
41.8 μM
Compound: 6
|
Cytotoxicity against human DLD1 cells co-transfected with Sac1 after 24 hrs
Cytotoxicity against human DLD1 cells co-transfected with Sac1 after 24 hrs
|
[PMID: 19682913] |
| L929 | IC50 |
2 nM
Compound: PAP-1
|
Inhibition of human voltage-gated potassium channel Kv1.3 expressed in L929 cells by whole-cell patch clamp assay
Inhibition of human voltage-gated potassium channel Kv1.3 expressed in L929 cells by whole-cell patch clamp assay
|
[PMID: 20971642] |
| RAW264.7 | IC50 |
2.2 μM
Compound: Cardamonin
|
Inhibition of LPS-induced NO production in mouse RAW264.7 cells pretreated for 30 mins followed by LPS challenge measured after 12 hrs by Griess assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells pretreated for 30 mins followed by LPS challenge measured after 12 hrs by Griess assay
|
[PMID: 28011215] |
| RAW264.7 | IC50 |
2.2 μM
Compound: Cardamonin
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 12 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 12 hrs by Griess assay
|
[PMID: 28688956] |
| RAW264.7 | IC50 |
11.48 μM
Compound: 8a
|
Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced NO production after 17 to 20 hr by Griess assay
Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced NO production after 17 to 20 hr by Griess assay
|
10.1007/s00044-011-9706-1 |
| THP-1 | IC50 |
1.1 μM
Compound: 139
|
Antiinflammatory activity in human THP-1 cells assessed as decrease in LPS-induced TNFalpha expression by Western blot analysis
Antiinflammatory activity in human THP-1 cells assessed as decrease in LPS-induced TNFalpha expression by Western blot analysis
|
[PMID: 37683361] |
In Vitro
Cardamonin (5-40 μM, 24 or 48 h) treatment inhibits gastric cancer cell growth[3].
Cardamonin (10-30 μM, 24 or 48 h) treatment can regulate the expression of apoptosis relative protein[3].
Cardamonin (10-30 μM, 24 or 48 h) treatment can inhibit STAT3 phosphorylation[3].
Cardamonin (0-100 μM, 24 h) treatment improves the anti-oxidative capacity in HL-1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AGS, MGC-803, BGC-823 cells
-
Concentration:5, 10, 20, 30, 40 μM
-
Incubation Time:24 or 48 hours
-
Result:Inhibited cell growth in a concentration-dependent manner.
-
Cell Line:AGS, MGC-803, BGC-823 cells
-
Concentration:10, 20, 30 μM
-
Incubation Time:24 or 48 hours
-
Result:Down-regulated Bcl-2, increased Bax protein expression, and increased the protein expression levels of Caspase-3.
-
Cell Line:AGS cells
-
Concentration:10, 20, 30 μM
-
Incubation Time:24 or 48 hours
-
Result:Suppressed the phosphorylation level of STAT3.
-
Cell Line:HL-1 cells
-
Concentration:0, 25, 50, 100 μM
-
Incubation Time:24 hours
-
Result:Showed anti-oxidant effects in doxorubicin-stimulated cardiomyocytes.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 J mice (8 weeks old, 20-22 g)[4]
-
Dosage:20, 40 or 80 mg/kg
-
Administration:Oral gavage; 20, 40 or 80 mg/kg; once
-
Result:Rescued the reduction of LVEF% and LVFS% by doxorubicin, reduced the increasement of serum LDH, CK-MB and Tn-T levels by doxorubicin in a dose-dependent manner, improved doxorubicin-induced histological changes, and attenuated collagen accumulation in cardiac sections by doxorubicin in a dose-dependent manner.
-
Animal Model:Male C57BL/6 J mice (8 weeks old, 20-22 g)[4]
-
Dosage:20, 40 or 80 mg/kg
-
Administration:Oral gavage; 20, 40 or 80 mg/kg; once
-
Result:Rescued Bcl-2, and inhibited Bax and Caspase-3 cleavage in heart tissues from doxorubicin-challenged mice.
Chemical Information
-
CAS No. 18956-16-6
-
Appearance Solid
-
Masse moléculaire 270.28
-
Formule C16H14O4
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(OC)C=C(O)C=C1O)/C=C/C2=CC=CC=C2
-
Synonyms
Cardamomin; Alpinetin chalcone
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Sulfation of chondroitin and bile acids converges to antagonize Wnt/ β-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis. [Abstract]2024 Mar;14(3):1241-1256. PMID: 38487006 -
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Pharmacol Res
Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]2020 May:155:104751. PMID: 32151678 -
Phytomedicine
2025 Dec:149:157512. PMID: 41240540 -
Phytomedicine
2024 Nov:134:155970. PMID: 39178681 -
Antioxidants (Basel)
A Combination of Cardamonin and Doxorubicin Selectively Affect Cell Viability of Melanoma Cells: An In Vitro Study. [Abstract]2024 Jul 19;13(7):864. PMID: 39061932 -
Phytother Res
Cardamonin attenuates cerebral ischemia/reperfusion injury by activating the HIF-1α/VEGFA pathway. [Abstract]2022 Apr;36(4):1736-1747. PMID: 35142404 -
J Agric Food Chem
Nephroprotective Effects of Cardamonin on Renal Ischemia Reperfusion Injury/UUO-Induced Renal Fibrosis. [Abstract]2023 Sep 13;71(36):13284-13303. PMID: 37646396 -
Food Funct
Cardamonin protects against diabetic cardiomyopathy by activating macrophage NRF2 signaling through molecular interaction with KEAP1. [Abstract]2024 Nov 11;15(22):11083-11095. PMID: 39431579 -
Food Funct
Cardamonin inhibits osteogenic differentiation of human valve interstitial cells and ameliorates aortic valve calcification via interfering in the NF-κB/NLRP3 inflammasome pathway. [Abstract]2021 Nov 29;12(23):11808-11818. PMID: 34766179 -
Nutrients
Inhibitory Effect of Tangeretin and Cardamonin on Human Intestinal SGLT1 Activity In Vitro and Blood Glucose Levels in Mice In Vivo. [Abstract]2021 Sep 26;13(10):3382. PMID: 34684383 -
Int J Mol Sci
Integrating Network Pharmacology, Machine Learning, and Experimental Validation to Elucidate the Mechanism of Cardamonin in Treating Idiopathic Pulmonary Fibrosis. [Abstract]2025 Dec 25;27(1):249. PMID: 41516127 -
ACS Omega
Receptor-Selective Modulation of Cannabinoid Signaling by Cardamonin: Integrating Molecular Dynamics, Free Energy Calculations, and Behavioral Validation. [Abstract]2026 Apr 13;11(16):23820-23832. PMID: 42077871 -
Sci Rep
Cardamonin inhibits the growth and stemness of osteosarcoma stem cells by inducing autophagy and inhibiting the Wnt/β-catenin signaling pathway. [Abstract]2025 Aug 12;15(1):29484. PMID: 40796594 -
Pathol Res Pract
Network pharmacology-based identification of cardamomin as a ferroptosis inhibitor in ischemic stroke via SP1/ALOX5 axis. [Abstract]2026 May 24:286:156558. PMID: 42208355 -
Toxicol Appl Pharmacol
Cardamonin attenuates osteoporosis progression and promotes osteogenic differentiation of bone mesenchymal stem cells by upregulating TCF4 expression. [Abstract]2026 Mar:508:117731. PMID: 41581571 -
Toxicol In Vitro
The natural chalcone cardamonin selectively induces apoptosis in human neuroblastoma cells. [Abstract]2023 Sep:91:105625. PMID: 37268255 -
Neurol Res
2025 Nov 25:1-17. PMID: 41289366 -
Biomed Pharmacother
Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling. [Abstract]2020 Feb:122:109547. PMID: 31918264
Cardamonin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Feb:122:109547. [Abstract]
Cardamonin promotes the Nrf2-ARE regulated cytoprotective genes in HL-1 cells dependent on Nrf2. western blot analysis were used to determine Nrf2, HO1, NQO1 and GCLM expression levels in HL-1 cells treated with the indicated concentrations of CAR (0, 25, 50 and 100 μM) for 24 h.
Cardamonin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Feb:122:109547. [Abstract]
Cardamonin promotes the Nrf2-ARE regulated cytoprotective genes in HL-1 cells dependent on Nrf2. Western blot analysis of Nrf2, HO1, NQO1 and GCLM.
Solvant et solubilité
In Vitro:
DMSO : 125 mg/mL (462.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (8.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Javaria Nawaz, et al. Cardamonin: A new player to fight cancer via multiple cancer signaling pathways. Life Sci. 2020 Jun 1;250:117591. [Content Brief]
[2]. Kai Wang, et al. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. Biochem Pharmacol. 2018 Sep;155:494-509. [Content Brief]
[3]. Zheng Wang, et al. Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axis. Biosci Rep. 2019 May 17;39(5):BSR20190357. [Content Brief]
[4]. Wang Qi, et al. Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling. Biomed Pharmacother. 2020 Feb;122:109547. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | 92.4967 mL |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | 18.4993 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL | 9.2497 mL | |
| 15 mM | 0.2467 mL | 1.2333 mL | 2.4666 mL | 6.1664 mL | |
| 20 mM | 0.1850 mL | 0.9250 mL | 1.8499 mL | 4.6248 mL | |
| 25 mM | 0.1480 mL | 0.7400 mL | 1.4799 mL | 3.6999 mL | |
| 30 mM | 0.1233 mL | 0.6166 mL | 1.2333 mL | 3.0832 mL | |
| 40 mM | 0.0925 mL | 0.4625 mL | 0.9250 mL | 2.3124 mL | |
| 50 mM | 0.0740 mL | 0.3700 mL | 0.7400 mL | 1.8499 mL | |
| 60 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5416 mL | |
| 80 mM | 0.0462 mL | 0.2312 mL | 0.4625 mL | 1.1562 mL | |
| 100 mM | 0.0370 mL | 0.1850 mL | 0.3700 mL | 0.9250 mL |
Cardamonin Related Classifications
HY-N0279 Related Classifications
Powered by Bioz